Výsledky vyhledávání - "G Hantsbarger"

P315 High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study

Autor: C Karki, E Sharpe, G Hantsbarger, K Lee, M Perovic, L Raven, M Sajak-Szczerba, A Silber, A Yoon, P Tozer

Publikováno v: Journal of Crohn's and Colitis. 16:i338-i339

Background Perianal fistulas (PAF) are a common complication in Crohn’s disease (CD) and can be associated with an increased burden of illness. A global study was conducted to assess the burden of illness in patients with Crohn’s perianal fistula

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce4233e717baf1b7108d0ac6fdbabfec
https://doi.org/10.1093/ecco-jcc/jjab232.442

Zobrazit plný text záznamu

P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulas

Autor: O Zmora, D C Baumgart, W Faubion, M Ferrante, K Gecse, E Genestin, P Geransar, G Hantsbarger, C Karki, P Tozer, J Panés

Publikováno v: Journal of Crohn's and Colitis. 16:i536-i537

Background Darvadstrocel (DVS) is a suspension of expanded allogeneic adipose-derived mesenchymal (stromal) stem cells approved for the treatment of complex Crohn’s perianal fistulas (complex CPF). The INSPIRE (EUPAS24267) registry is a European ob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f45ae5f857ebb2bfed9752661e6a5fc
https://doi.org/10.1093/ecco-jcc/jjab232.729

Zobrazit plný text záznamu

P585 Examining faecal incontinence and its impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a multi-country burden of illness study

Autor: C Karki, A Athavale, G Hantsbarger, K Lee, S Milicevic, M Perovic, L Raven, M Sajak-Szczerba, E Sharpe, P Tozer

Publikováno v: Journal of Crohn's and Colitis. 16:i523-i524

Background Perianal fistulas (PAF) are a common complication associated with Crohn’s disease (CD), and patients with Crohn’s perianal fistulas (CPF) are more likely to experience faecal incontinence (FI) than patients with CD without PAF (non-PAF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ca6c6acc9306f7c86b7767c6baae016
https://doi.org/10.1093/ecco-jcc/jjab232.711

Zobrazit plný text záznamu

P516 Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study

Autor: C Karki, A Athavale, G Hantsbarger, K Lee, S Milicevic, M Perovic, L Raven, M Sajak-Szczerba, V Abilash, P Tozer

Publikováno v: Journal of Crohn's and Colitis. 16:i472-i473

Background Perianal fistulas (PAF) are a common complication of Crohn’s disease (CD) and patients with Crohn’s perianal fistulas (CPF) experience low health-related quality of life and a higher burden of symptoms than patients with CD without PAF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e7b1ed5bfd0a8a2993f7fe6752d18e7
https://doi.org/10.1093/ecco-jcc/jjab232.643

Zobrazit plný text záznamu

DOP57 Predictive modelling to examine long term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s Disease

Autor: I Gilaberte, E Turkstra, M Maruszczak, C Karki, K Genenz, J Panes, G Hantsbarger, E Fenu

Publikováno v: Journal of Crohn's and Colitis. 15:S092-S093

Background Darvadstrocel (DVS) was approved in 2018 by EMA for treatment of complex perianal fistulas in Crohn’s disease (CPF-CD)1, with evidence on long-term effectiveness still accruing. The objective of this study was to synthesize clinical tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6965be485204f37307175f61a41af2d2
https://doi.org/10.1093/ecco-jcc/jjab073.096

Zobrazit plný text záznamu

P340 Real-world treatment patterns and recurrence rates of rectovaginal fistulas in patients with Crohn’s disease: A retrospective cohort database analysis

Autor: I Gilaberte, Dominick Latremouille-Viau, C Karki, H Romdhani, G Hantsbarger, Amy L. Lightner

Publikováno v: Journal of Crohn's and Colitis. 15:S364-S365

Background Rectovaginal fistulas (RVF) are a difficult to treat perianal complication of Crohn’s disease (CD) with a significant impact on quality of life. Management of RVF includes both medical and surgical interventions. Few studies have assesse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82583b1850e1a46711c6d17e6027aa4c
https://doi.org/10.1093/ecco-jcc/jjab076.464

Zobrazit plný text záznamu

P600 Vedolizumab dose optimisation: Findings from a Belgian registry

Publikováno v: Journal of Crohn's and Colitis. 14:S501-S502

Background Vedolizumab (VDZ) dose optimisation (DO), by interval shortening from 8-weekly (Q8W) to 4-weekly (Q4W) dosing, is used for patients with secondary loss of response. This report presents outcome data on patients receiving DO in real-world c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b2a7a420544275b5739e90e5f5981fd0
https://doi.org/10.1093/ecco-jcc/jjz203.728

Zobrazit plný text záznamu

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data

Autor: Timothy R. Card, Aimee Blake, G Hantsbarger, Simon Travis, Ryan C. Ungaro, Fatima Bhayat

Publikováno v: Alimentary pharmacologytherapeutics. 51(1)

Background: Vedolizumab is a gut‐selective antibody to α4β7 integrin approved to treat moderate‐to‐severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::175c77031c6c4ebc284b45d4289563d7
https://pubmed.ncbi.nlm.nih.gov/31747086

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání